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Summary 
Background 
Orphan drug regulation was created out of the idea that patients suffering 
from rare conditions should be entitled to the same quality of treatment as 
other patients.Some conditions however, are so rare that a thorough clinical 
development programme, normally required, is practically impossible. In 
these casesthe European Medicines Agency (EMA) can authorise a drug un-
der exceptional circumstances. 
Aim and research questions 
This report aims to provide insight into the authorisation under exceptional 
circumstances of oncology drugs. We try to answer the following questions: 
b What clinical data were presented by the applicant and what were the 
considerations by the Committee for Medicinal Products for Human 
Use (CHMP) for granting exceptional circumstances? 
b What were the additional requirements to be fulfilled by the 
marketing authorisation holder? 
b What additional data became available on the originally licenced 
indication and did it confirm the initial expectations? 
b How do reimbursement agencies assess these drugs? 
b Are there any patient access schemes for these drugs? 
b Do the patients have access to the drugs? 
Methods 
This report considered oncology drugs currently licenced under exceptional 
circumstances. Reimbursement agencies from England, Scotland, Belgium, 
France and the Netherlands were included. A MEDLINE-search for litera-
ture was performed through Pubmed and grey literature was included from 
EMA and the reimbursement agencies.  
Results 
Four oncologic drugs are currently licensed under exceptional circumstances; 
clofarabine, nelarabine, trabectedin and histamine dihydrochloride. Hista-
mine dihydrochloride was the only drug tested in a phase III trial. For clo-
farabine, nelarabine and trabectedin the justification for the authorisation 
under exceptional circumstances was the small size of the patient population. 
For histamine dihydrochloride it was unclear. Most of the additional re-
quirements by the CHMP considered safety measures and they were not al-
ways completed within the set time-frame.  
The methods of the reimbursement assessments varied. One patient access 
scheme was identified for trabectedin in England. Some of the drugs were 
not accessible in some countries and for others it was unclear.  
Conclusion and recommendation 
To successfully develop drugs for very rare conditions, it is important that 
industry, EMA and reimbursement agencies intensify the collaboration. On 
introduction these drugs cannot always prove their cost-effectiveness, there-
fore conditional coverage with evidence development, preferably on an in-
ternational level, should be encouraged and facilitated.  
background 
aim and research 
questions 
methods 
results 
conclusion and 
recommendations 
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1 Introduction 
Since the founding of the European Medicines Agency (EMA) in 1995, over 
fifty novel oncologic drugs have reached the European market. Despite ad-
vances in the development of cancer drugs in the last decades, there is still a 
high medical need for curative therapies. To accelerate patient access to new 
treatments in all fields of medicine and to stimulate research by pharmaceu-
tical companies, the European Commission has laid down multiple regula-
tions concerning marketing authorisation for pharmaceuticals.  
As stated in Regulation (EC) No 141/2000, orphan drug regulation was cre-
ated out of the idea that patients suffering from rare conditions should be 
entitled to the same quality of treatment as other patients. The pharmaceu-
tical industry would be unwilling to develop the medicinal product for rare 
diseases under normal market conditions, because the costs of developing 
and bringing to the market of such a product would not be recovered by the 
expected sales [1]. 
Patients with such conditions deserve the same quality, safety and efficacy 
in medicinal products as other patients, therefore orphan medicinal prod-
ucts are submitted to the normal evaluation process [1]. Some conditions 
however, are so rare that a thorough clinical development programme, nor-
mally required, is practically impossible. In this case it is possible to get a 
marketing authorisation under exceptional circumstances [2].  
There are some possible pitfalls to this policy. There are no extensive guide-
lines on when exceptional circumstances are applicable, which gives the 
Committee for Medicinal Products for Human Use (CHMP) freedom to ap-
ply them when they think it is appropriate. It also is unclear what the condi-
tions and arguments are to apply this policy and whether they are justified.  
Secondly, this policy somewhat contradicts the statement that patients with 
rare diseases deserve the same quality, safety and efficacy in medicinal prod-
ucts as other patients. Especially the latter two aspects could be expected to 
be less convincing when a thorough clinical development programme is 
lacking. 
Thirdly, it conflicts with the so called ‘fourth hurdle’ in drug development. 
To gain market access and reimbursement, the demonstration of clinical- 
and cost-effectiveness are in some countries a necessity [3, 4]. A limited 
clinical development programme could possibly not satisfy the requirements 
for reimbursement. For these reasons, it is thinkable that a marketing au-
thorisation under exceptional circumstances might not always have its de-
sired effect in providing safe and effective medicines to seriously ill patients.  
Concerns have been raised by Niraula et al [5] about the safety of newly ap-
proved cancer drugs in general. The greater efficacy of these drugs seems to 
come with an increase in morbidity and treatment-related mortality, owing 
to the toxicity of the treatments. This may be a consequence of the fact that 
oncology drugs are often approved without a phase III trial [6] and that the 
pivotal trial design for orphan oncology drugs, but also for non-orphan on-
cology drugs, is often far from ideal [7-10]. 
A study conducted by EURORDIS in 2006 analysed the availability of 21 
different orphan drugs in 28 European countries [11]. The results showed 
that there was a large variation in access to orphan drugs. Only in four coun-
rationale for orphan 
drug regulation 
some conditions are too 
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clinical development 
programme 
no extensive guidelines 
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circumstances 
lacking of thorough 
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reimbursement 
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tries nearly all drugs were available to patients. The four oncologic drugs 
that were assessed in the EURORDIS study were available to around 70 % 
of the total population included.  
In the past decade, a lot of attention has been given to orphan drugs and or-
phan drug regulation. In this report, we focus explicitly on oncology drugs 
authorised under exceptional circumstances.  
 
 
1.1 Aim and objectives 
This report aims to provide insight into the authorisation under exceptional 
circumstances of oncology drugs by exploring the possible pitfalls presented 
earlier. We try to answer the following questions: 
b What clinical data were presented by the applicant and what were the 
considerations by the CHMP for granting exceptional circumstances? 
b What were the additional requirements to be fulfilled by the 
marketing authorisation holder? 
b What additional data became available on the originally licenced 
indication and did it confirm the initial expectations? 
b How do reimbursement agencies assess these drugs? 
b Are there any patient access schemes for these drugs? 
b Do the patients in the selected countries have access to the drugs? 
 
 
1.2 Materials and Methods 
Product selection 
Drugs licensed under exceptional circumstances were identified via the web-
site of the EMA using the European Public Assessment Report (EPAR) da-
tabase. Only new chemical or biological entities, currently authorised under 
exceptional circumstances by the European Commission for anticancer treat-
ment were included. Supportive therapies (e.g. bisphosphonates, immuno-
globulins, antiemetics), colony-stimulating factors, chemoprevention treat-
ments, vaccines and generics were excluded. Label extensions obtained after 
the initial marketing authorisation were not considered.  
 
Selection reimbursement agencies 
The main inclusion criteria for the reimbursement agencies were the exis-
tence of publicly available assessment reports in Dutch, English or French 
and the nationwide reach of their advice. Because this report considers EMA 
regulation, only European agencies were included. The inclusion of England, 
Scotland, Belgium, France and the Netherlands was an unsystematic selec-
tion.  
 
research questions 
oncology drugs licenced 
under exceptional 
circumstances 
Belgium, England, 
France, the Netherlands 
and Scotland were 
included 
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Search strategy 
For the overview of the additional clinical evidence a MEDLINE-search was 
performed via Pubmed for all clinical studies concerning the original licenced 
indication. The search terms were the name of the product and the indica-
tion. Unpublished studies were identified through regulatory documents from 
EMA and the trial registry clinicaltrials.gov. Reimbursement documents were 
retrieved from the websites of the assessing agencies.  
 
Data extraction 
Information on the name of the active substance, date of approval, initial in-
dication, the clinical data of the pivotal studies, the risk-benefit assessment 
by the CHMP and additional requirements for the marketing authorisation 
holder was extracted from the EPAR. For the overview of the additional evi-
dence information was extracted on the type of study, indication, number of 
patients and for two products also the main outcome. For the analysis of the 
reimbursement assessments, the main remarks on the effectiveness, safety, 
cost-effectiveness, budget impact, severity of disease and ease of use were ex-
tracted as well as the conditions to the reimbursement, including patient ac-
cess schemes, and the final recommendation.  
 
 
main sources:  
EMA, MEDLINE, 
clinicaltrials.gov and 
reimbursement agencies 
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2 Background 
This chapter gives an overview of all the relevant regulations and policies, 
additional information on reimbursement strategies, information on the se-
lected reimbursement agencies and an introduction to the financing of on-
cology drugs. 
 
 
2.1 EMA 
2.1.1 Authorisation procedures  
for medicinal products in the European Union 
The European system offers several routes for introducing a medicinal prod-
uct to the European market. 
The Centralised Procedure allows for authorisation of medicinal products to 
the entire market of the European Community through a single application 
and evaluation by the EMA [12]. Within the EMA, the CHMP is responsible 
for preparing the Agency’s opinions on all questions concerning medicines 
for human use. The procedure is laid down in Regulation (EC) No 726/2004 
of the European Parliament and of the Council of 31 March 2004 [1].  
The centralised procedure is mandatory for all medicinal products derived 
from biotechnology, designated orphan products and new actives substances 
intended for the treatment of acquired immune deficiency syndrome, cancer, 
neurodegenerative disorders, diabetes, auto-immune diseases, immune dys-
functions and viral diseases. The procedure is optional for other new active 
substances and medicinal products that constitute a significant therapeutic, 
scientific or technical innovation. Generic applications for active substances 
that have already been authorised via the centralised procedure have au-
tomatic access to the centralised procedure.  
After applicants have notified the EMA of their intention to submit an ap-
plication, a Rapporteur and Co-Rapporteur are appointed from amongst the 
members of the CHMP. The role of the Rapporteur is to perform the scien-
tific evaluation and to prepare an assessment report to the CHMP. This as-
sessment report receives comments from other CHMP members which are 
incorporated into the report and communicated to the applicant. After sub-
mitting the applicants’ replies to the CHMP for discussion, the Rapporteur 
and Co-Rapporteur prepare a final assessment report. The CHMP then gives 
a favourable or unfavourable opinion as to whether to grant the authorisation. 
The time limit for this procedure is 210 days, with the possibility for the ap-
plicant to apply for an accelerated assessment of max 150 days, when it con-
cerns a product of major public health interest. The decision is ultimately 
made by the European Commission. A European Public Assessment Report 
(EPAR) will be published when the Commission issues its decision. When 
the decision is negative, a “Refusal EPAR” is published.  
 
centralised Procedure 
laid down in Regulation 
(EC) No 726/2004 
centralised procedure  
is mandatory for orphan 
drugs and innovative 
oncologic drugs 
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Under normal circumstances, the marketing authorisation is valid for five 
years. After five years the CHMP re-evaluates the benefit-risk balance of the 
product. When the marketing authorisation gets renewed, it will be valid for 
an unlimited period, unless otherwise specified.  
There are other options for gaining marketing authorisation in the European 
Communion. The mutual recognition procedure is intended for products that 
have already got authorisation in one of the Member States, which will be 
recognised by other Member States. The decentralised procedure is like the 
mutual recognition procedure, also based on recognition by national authori-
ties of a first assessment performed by one Member State. The difference is 
that it applies to medicinal products which have not received a marketing 
authorisation in any European member state at the time of application. Also 
national authorisations are still available for medicinal products to be mar-
keted in one Member State only, when the centralised procedure is not man-
datory. 
 
2.1.2 Orphan Medicinal Product Designation 
Orphan drug regulation is not a European invention. The Orphan Drug Act 
(ODA) from 1983 is said to be one of the most successful United States legis-
lative actions in recent history [13]. Similar regulations came into force in 
Singapore (1991), Japan (1993), Taiwan and Australia (1998) and lastly in the 
EU (2000) [14]. The European parliament and the Council of Europe have 
adopted the regulation (EC) No 141/2000 of 16 December 1999 on orphan 
medicinal products, with the intention to stimulate research, development 
and bringing to the market of medications for rare conditions [1]. This regu-
lation gives developers of medicinal products the opportunity to apply for 
orphan designation for their product, providing them with various advan-
tages in the field of protocol assistance, access to the Centralised Procedure 
and marketing exclusivity. 
In the EU, medicinal products are eligible for orphan designation if it is in-
tended for the diagnosis, prevention or treatment of a life-threatening or 
chronically debilitating condition affecting not more than 5 in 10,000 people 
in the European Community at the time of the application or if it is unlikely 
that without incentives the marketing of the medicinal product would gen-
erate sufficient return to justify the necessary investment. Additionally there 
needs to be an absence of alternatives and if such an alternative does exist, 
the medicinal product needs to be of significant benefit to the people affected 
by the condition [1].  
An application for orphan designation can be submitted any time before the 
application for marketing authorisation is made. The Committee for Orphan 
Medicinal Products is responsible for examining the applications. Designated 
medicinal products are entered in the Community Register of Orphan Me-
dicinal Products. The sponsor has to report to the EMA on the state of de-
velopment of the product on a yearly basis. Designated products can be re-
moved from the register for three reasons: 1) at request of the sponsor, 2) if it 
is established that the criteria for designation are no longer met or 3) at the 
end of the period of market exclusivity.  
a normal marketing 
authorisation is valid for 
five years 
beside the centralised 
procedure there is the 
mutual recognition 
procedure and the 
decentralised procedure 
orphan drug regulation 
has been implemented 
in 2000 in Europe 
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10,000 people in the EU 
are affected 
orphan designation is 
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Medicinal Products 
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The developer of a designated product may request protocol assistance in the 
development of the product before marketing authorisation and can apply 
for various fee reductions on protocol assistance, pre-authorisation inspec-
tions, the initial application, post authorisation applications and the first an-
nual fee. Most importantly however, the sponsor can get market exclusivity 
for 10 years, wherein no similar medicinal product for the same therapeutic 
indication shall be granted marketing authorisation. Exceptions can be made 
when either the holder of the original marketing authorisation has given his 
consent or is unable to supply the product in sufficient amounts or the sec-
ond medicinal product is clinically superior. The market exclusivity can also 
be reduced to six years, if at the end of the fifth year is established that 
original designation criteria are no longer met.  
 
2.1.3 Applications in exceptional circumstances 
The procedure for granting a marketing authorisation under exceptional cir-
cumstances is outlined in a guideline published by EMA [2]. A marketing 
authorisation may be granted under exceptional circumstances when an ap-
plicant for marketing authorisation is unable to provide comprehensive data 
on the efficacy and safety under normal conditions of use because of one of 
the following reasons: 
b the indication is too rare; 
b the present state of scientific knowledge needed to provide 
comprehensive information is insufficient; 
b it would be unethical to collect such information. 
Once exceptional circumstances are granted, the applicant may be subjected 
to specific obligations such as additional efficacy or safety studies, there may 
be restrictions on the setting in which the product is used (e.g. inpatient or 
outpatient) and there may be additional requirements to the package leaflet 
and medical information of the product.  
Marketing authorisations under exceptional circumstances are reviewed on 
an annual basis to reassess the risk-benefit balance. The fulfilment of the 
specific obligations concerning the provision of additional efficacy or safety 
data will normally not lead to the completion of a full dossier and a normal 
marketing authorisation. If it is expected that the applicant can confirm the 
positive benefit/risk balance with a full dossier in the future, the product 
could be authorised under conditional approval. This temporary authorisa-
tion is also assessed annually and is not intended to remain conditional. Or-
phan designation criteria are independent from the criteria to be considered 
for approval under exceptional circumstances [2]. 
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reductions and 10 year 
market exclusivity 
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2.1.4 Conditional approval 
Medicinal products are eligible for conditional approval by the EMA if they 
belong to one of the three following categories: 
b medicinal products which aim at the treatment, the prevention or the 
medical diagnosis of seriously debilitating diseases or life-threatening 
diseases; 
b medicinal products to be used in emergency situations, in response to 
public threats duly recognised either by the WHO or by the Commu-
nity in the framework of Decision (EC) No 2119/98; 
b medicinal products designated as orphan medicinal products in ac-
cordance with Article 3 of Regulation (EC) No 141/2000. 
Additionally they have to meet all of the following requirements: 
b the risk-benefit balance of the medicinal product is positive; 
b it is likely that the applicant will be in a position to provide the com-
prehensive clinical data; 
b unmet medical needs will be fulfilled; 
b the benefit to public health of the immediate availability on the mar-
ket of the medicinal product concerned outweighs the risk inherent 
in the fact that additional data are still required. 
Conditional marketing authorisations are valid for one year and can be re-
newed. As with exceptional circumstances, specific obligations may be im-
posed in relation to the collection of data. The main difference is that the 
authorisation is not intended to remain conditional.  
Before conditional approval was introduced in 2006, authorisations that 
should have fallen into this category were authorised under exceptional cir-
cumstances. Therefore a lot of drugs that were initially authorised under ex-
ceptional circumstances now have a regular marketing authorisation [15].  
 
 
2.2 Reimbursement aspects 
2.2.1 Healthcare systems introduction 
There is a variety in the way healthcare systems are organized in Europe. 
Most countries have either a national health service (England and Scotland) 
or an insurance-based healthcare system (Belgium, France and the Nether-
lands. The insurance-based systems can be either ‘social’ or ‘private’ [16]. 
Social insurance-based healthcare systems rely on the principle of solidarity 
in population coverage, funding and benefits package. They have the impor-
tant commonalities that the contributions are risk independent, i.e. they are 
not linked to health status, and they are transparently collected independent 
from state general revenues [17]. Private insurance-based healthcare systems, 
like in the United States of America, are not common in Europe. The ones 
that do exist work under social conditions, which means acceptance is man-
datory (the Netherlands). However, in almost all European member states it 
is possible to buy additional private insurance [16]. 
conditional approval  
is possible when the 
risk-benefit balance is 
positive, but part of the 
clinical data is still 
awaited 
a high medical need 
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valid for one year 
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A national health service is primarily funded through general taxation ra-
ther than requiring insurance payments. Table 2.2-1 lists an overview of the 
main characteristics of the countries included in the report.  
 
2.2.2 Reimbursement and financing aspects 
Reimbursement of pharmaceuticals for outpatient use is often established in 
a positive list; a legally binding index of pharmaceuticals that are reim-
bursed by the national health service/health insurance system. A negative 
list is also a possibility, in which case certain pharmaceuticals are specifically 
excluded from reimbursement/funding. Belgium, France and the Nether-
lands work with a positive outpatient list. England and Scotland work with a 
negative list. For inpatient use, national lists of pharmaceuticals are less 
common, but Belgium and France have a positive list for inpatient pharma-
ceuticals. England and Scotland have a negative list for inpatient pharma-
ceuticals [16]. 
Co-payments on pharmaceuticals are common in almost all healthcare sys-
tems, but differ in quantity and form. They can be found in the form of 
fixed-fees, prescription-fees, percentages of the price of the pharmaceutical 
or the difference between the list price and the retail price (see Table 2.2-1).  
Oncology drugs are dispensed and administered in both the inpatient and 
outpatient setting. Some of them are suitable for self-administration, mainly 
those that can be taken orally or certain injectable dosage forms, and they 
can be dispensed by community pharmacies. Other dosage forms, like intra-
venous infusions, are mainly administered in a clinical setting, often the 
hospital. The setting in which the drugs are used is in most countries of in-
fluence on the way they are financed. 
Table 2.2-2 show an overview of the agencies and institutes involved in re-
imbursement assessments and decisions in the selected countries. 
 
Belgium 
The healthcare system in Belgium is a social insurance-based system and it’s 
for the largest part funded from health insurance contributions, general tax-
ation and co-payments. In Belgium, co-payments on outpatient pharmaceu-
ticals are common, but on life-saving drugs there is no co-payment. For in-
patient drugs patients pay € 0,62 per hospitalisation day [18]. 
Reimbursement assessments are performed by the National Institute for 
Sickness and Invalidity Insurance (RIZIV). They are initiated by an applica-
tion from the manufacturer. The assessment is based on the therapeutic val-
ue, which includes effectiveness, safety, applicability and ease of use, price, 
medical need, budget impact and cost-effectiveness. On the basis of the ad-
vice from RIZIV, the Ministry of Social Affairs will make a reimbursement 
decision. Since Belgium works with a positive list for both in- and outpatient 
pharmaceuticals, only evaluated pharmaceuticals are eligible for reimburse-
ment [16]. 
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England 
The National Health Service in the United Kingdom is a publicly funded 
health system. Although it is funded from national taxation, the National 
Health Service (England), the Health and Social Care in Northern Ireland 
(HSENI), the NHS Scotland and the NHS Wales are managed separately. 
The NHS England is divided into 10 Strategic Health Authorities, which 
supervise all NHS trusts in their respective area. The primary care trusts are 
local organisations in charge of primary care and control 80 % of the NHS 
budget. They allocate the budgets to the hospitals [19]. 
The National Institute for Health and Clinical Excellence (NICE) was set up 
in 1999 to reduce variation in the availability and quality of NHS treatments 
and care. NICE develops evidence-based guidelines on diagnosing, treatment 
and prevention [20].The Centre for Health Technology Evaluation (CHTE), 
within NICE, develops single technology appraisals, which are recommen-
dations on the use of new and existing medicines and treatments within the 
NHS. The development of a single technology appraisal is quite an extensive 
process. The topics are referred to NICE by the Department of Health. Then 
evidence is gathered from both the manufacturer and independent consultees. 
The evidence is reviewed by an independent academic centre after which 
clinical experts, patients and carers can comment on it. The appraisal com-
mittee then produces its final appraisal determination with recommendations 
on how the technology should be used in the NHS in England and Wales. 
Within this process there are several moments for stakeholders, such as the 
manufacturer and patient representatives, to comment, discuss or appeal. 
Once finalised, the advice issued by NICE is binding for the primary care 
trusts and funding has to be available within three months [21].  
NICE maintains a strict maximum ICER of £ 30,000 per QALY gained when 
recommending technologies, but has the option to make exemptions for life-
extending, end of life treatments. The three main criteria that are to be satis-
fied are 1) the treatment is indicated for patients with a short life expec-
tancy, normally less than 24 months and; 2) there is sufficient evidence to 
indicate that the treatment offers an extension to life, normally of at least an 
additional 3 months, compared to current NHS treatment and; 3) the treat-
ment is licensed or otherwise indicated, for small patient populations [22].  
 
France 
After market authorisation of a pharmaceutical, the Transparency Committee 
of the Haute Authorité de Santé (HAS) evaluates the medical benefit (Service 
Médical Rendu, SMR) and the improvement in medical benefit (Améliora-
tion du Service Médical Rendu, ASMR). The SMR is a three point scale rang-
ing from SMR I; pharmaceutical of major therapeutic value to SMR III; 
pharmaceutical of insufficient therapeutic value and the ASMR is a six point 
scale ranging from ASMR I; significant therapeutic value to ASMR VI; nega-
tive opinion regarding inclusion into reimbursement. Subsequently the Trans-
parency Committee advices on inclusion on one or both of the positive lists; 
the outpatient list (la liste des medicaments remboursable sagrées aux assu-
rés sociaux) and the inpatient list (la listedes médicaments agrées aux collec-
tivités). The SMR determines the rate of reimbursement; 100 %, 65 % or 35 %. 
The reimbursement rate for cancer treatment is always 100 %. Inpatient 
pharmaceuticals are financed through a diagnosis related group-type system. 
Additionally there is the T2A-list of innovative and expensive pharmaceuti-
cals, that are financed separately [23]. 
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The Netherlands 
The reimbursement evaluation of pharmaceuticals is generally initiated by 
an application by the marketing authorization holder to the minister of 
Health, Welfare and Sports (VWS). The minister is assisted in her decision 
by the Healthcare Insurance Board (CVZ). Within the CVZ, the Committee 
Pharmaceutical Aid (CFH) will draw up an ‘assessment of therapeutic value’ 
and make a budget impact estimate. For new chemical entities, the CFH 
will also give an opinion on the justification of the efficiency (cost-effec-
tiveness). The therapeutic value of a pharmaceutical is based on five criteria: 
positive effects, negative effects, experience with the drug, applicability and 
ease of use. The weight of these criteria is carefully determined in each case. 
Costs play no role in the assessment of therapeutic value. Based on the re-
port from the CFH, the appraisal committee gives its opinion on the four 
principles of the benefits of Dutch basic health insurance, necessity (disease 
burden), effectiveness, cost-effectiveness and practicability. Based on the 
CFH and the appraisal committee reports, the CVZ issues an advice to the 
minister, who makes the ultimate decision to designate a pharmaceutical for 
reimbursement by the insurance companies [24]. 
Inpatient pharmaceuticals are not reimbursed by the health insurers, but are 
paid from the hospital budget. To counteract the so-called ‘postcode pre-
scribing’ (expensive pharmaceuticals only being available in certain regions 
or hospitals), two policies were introduced in 2006 to provide additional 
funding for really expensive innovative drugs (costs of at least 2,5 million 
Euros per drug per hospital per year) and orphan drugs (when the yearly 
costs of the drug exceed 5 % of the total drug budget). Applications for this 
funding cannot be made by the manufacturer, but have to be made by par-
ties like the clinicians organizations. Additionally, the funding is always 
conditional. After four years, the drug is reassessed on budget-impact, thera-
peutic value and cost-effectiveness. A dossier for this assessment has to be 
submitted by the party that originally applied for the funding, but the nec-
essary research is a joint responsibility of the manufacturer, clinicians and 
the healthcare institutes. As of 2012 these two policies are no longer active. 
Funding for these drugs is now included in the hospital budgets again. The 
evaluation process however, has not been changed [25-27]. 
 
Scotland 
In Scotland the Scottish Medicines Consortium (SMC) evaluates all newly 
licenced pharmaceuticals on the basis of a dossier submitted by the manu-
facturer. If the manufacturer decides not to submit a dossier, the SMC will 
not recommend a drug. The assessment performed by the SMC is based on 
the effectiveness, safety, target population, costs and cost-effectiveness. If the 
SMC recommends a pharmaceutical, local NHS boards have to decide if they 
want to include it into their local formulary. The NHS Quality Improvement 
Scotland considers if the advice given by NICE is relevant to patients in 
Scotland. If so, they publish the advice on their websites and the local NHS 
boards have to consider it for their local formularies [28].  
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Table 2.2-1: Main characteristics of the healthcare systems and reimbursement of pharmaceuticals of the countries included in the report 
 Belgium England France The Netherlands Scotland 
Type of healthcare system Insurance-based National health service Insurance-based Insurance-based National health service 
Health insurance is mandatory Yes NA Yes Yes NA 
Social insurance Yes No Yes No No 
Private insurance is the main type No No No Yes No 
Reimbursement list      
Type of list outpatient pharmaceuticals Positive Negative Positive Positive Negative 
Type of list inpatient pharmaceuticals Positive Negative Positive NA Negative 
Co-payments outpatient pharmaceuticals      
% of the price X  X   
Fixed fee   X   
Payment of difference between reference 
price and retail price X   X  
Prescription fee  X    
Deductible    X  
Annual co-payment ceiling X     
Source: Kleijnen et al, 2011 [16] 
Abbreveations: NA – Not applicable 
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Table 2.2-2: Agencies and organisations involved in reimbursement decisions in the countries included in the report 
 Belgium England France The Netherlands Scotland 
Reimbursement 
evaluations 
Always, inpatient and 
outpatient 
Always for branded, 
oncology an autoimmune 
disease, sometimes for 
generics and orphan 
Always for branded, 
oncology, autoimmune 
and orphan, sometimes 
generics 
Yes, not for generics, 
sometimes for inpatient 
use 
Always for oncology, 
autoimmune and 
orphan, sometimes for 
branded, never for 
generics 
Agency that 
performs the 
assessment 
INAMI/RIZIV (Institut 
national d’assurance 
maladie-invalidite´/ 
RijksInstituut voor  
Ziekte – en Invaliditeits 
Verzekering) 
Product sponsor/ 
academic group (rapid) 
academic group/ 
stakeholders (full) 
Haute Autorite´ de Sante´ 
(HAS) (French National 
Authority for Health) 
Health Care Insurance 
Board (CVZ) 
Scottish Medicines 
Consortium (SMC) 
Organisation that 
provides advice for 
the decision 
INAMI/RIZIV National Institute for 
Health and Clinical 
Excellence (NICE) 
HAS CVZ SMC 
Organisation that 
makes the decision 
Ministry of Social Affairs NICE/NHS primary care 
trust 
Ministry of Health and 
Social Affairs 
Ministry of Health, 
Welfare and Sport 
(VWS) 
Regional Health 
Authority 
Source: Kleijnen et al, 2011 [16] 
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2.2.3 Patient Access Schemes 
Where reimbursement decisions traditionally only focused on whether to pay 
for a product, for the entire indication, or for a particular subgroup, recently 
a number of new ways to finance pharmaceuticals have been introduced, so 
called patient access schemes. These schemes can be classified in different 
ways which are discussed below [29, 30]. 
 
Coverage with evidence development 
Coverage with evidence development (CED) can be divided into ‘only with 
research’ where all patients are given access to the treatment, but evidence is 
also generated, an ‘only in research’ where the treatment is only paid for pa-
tients involved in the research. These types of schemes are particularly use-
ful for treatments that appear promising, but may not yet have the required 
supporting evidence [29, 30]. The generating of additional evidence can take 
place in various settings. The marketing authorisation holder is not always 
the sole responsible party, but also patient organizations and scientific bodies 
can have interests in additional clinical evidence and proof of cost-effective-
ness, as it can assist in more adequate use of resources. CED has been stan-
dard practice for expensive or orphan, inpatient pharmaceuticals in the Neth-
erlands since 2006, with varying results.  
 
Conditional treatment continuation 
In conditional treatment continuation (CTC) a treatment will only continue 
to be reimbursed when a short-term target clinical effect is reached. These 
schemes require the existence of a short-term measure that is an acceptable 
surrogate for relevant clinical endpoints. CTC is particularly useful when 
doctors and patients are inclined to continue treatment merely because of a 
lack of alternatives [29]. An example of such a reimbursement scheme is the 
agreement between Johnson and Johnson and the UK’s NHS. Bortezomib, 
used in the treatment of progressive multiple myeloma, is only continued in 
people who have a complete or partial response, measured by serum M pro-
tein, after a maximum of four cycles. Johnson and Johnson rebates the full 
cost of bortezomib for people who have less than a partial response [31]. 
 
Performance linked reimbursement 
When the generation of more evidence is very expensive, but the manufac-
turer has sufficient confidence in its product or when a therapy is clearly ef-
fective in certain patients, but cost-effectiveness criteria are not reached, a 
performance-linked reimbursement scheme can be appropriate. The major-
ity of performance-linked reimbursement schemes involve rebates or refunds 
when a certain treatment goal is not reached [29]. A recent example of such a 
scheme is the pay-for-performance agreements of August 2012 between hospi-
tals in the Netherlands and Novartis, for the drug omalizumab (Xolair), used 
in the treatment of severe asthma. Novartis has agreed to pay for the treat-
ment of patients with omalizumab that turns out to be unsuccessful. The 
Dutch association of physicians for pulmonary disease is responsible for the 
inclusion and evaluation criteria of the patients and the hospital pharmacy is 
responsible for reclaiming the costs of omalizumab in case of an unsuccess-
ful treatment. For the Netherlands, this is the first pay-for-performance re-
imbursement scheme and therefore it will initially last for two years [32].  
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Non-outcome-based schemes 
Additional to these health-outcomes-based schemes, there are multiple non-
outcome-based schemes, where effective prices can be determined on a pa-
tient or population level. An example of a patient level scheme is the dis-
count on treatment initiation with sunitinib in renal cell carcinoma. The 
manufacturer of sunitinib (Pfizer) has agreed a patient access scheme with 
the Department of Health, in which the first treatment cycle of treatment is 
free to the NHS [33]. A fixed cost per patient is agreed between the manu-
facturer of gefitinib (Astra Zeneca) and the Department of Health. Gefitinib 
for first-line treatment of non-small cell lung cancer will be available at a 
single fixed cost of £ 12,200 per patient irrespective of the duration of treat-
ment. On top of that the manufacturer will not invoice the NHS until the 
third monthly pack of gefitinib is supplied. This means that treatment that 
lasts less than 3 months will not be charged by the manufacturer [34]. Popu-
lation level schemes include discounts for payers on the list price, total ex-
penditure caps and price/volume agreements [30]. 
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3 Results 
3.1 Oncology drugs under exceptional 
circumstances 
The search on the EMA website yielded that there are currently only four 
oncologic drugs authorised under exceptional circumstances; nelarabine, clo-
farabine, histamine dihydrochloride and trabectedin (Table 3.2-1). Seven 
other oncologic drugs have previously been authorised under exceptional 
circumstances, but later received a normal licence, with six being still on the 
market. (Alemtuzumab has been withdrawn for commercial reasons.)  
 
 
3.2 Clofarabine – Evoltra 
3.2.1 Indication 
Acute lymphoblastic leukaemia (ALL) is a cancer of the blood and bone mar-
row, in which too many immature lymphocytes are produced. Blood stem 
cells produced in the bone marrow can develop in either a myeloid stem cell 
or a lymphoid stem cell. Myeloid stem cells can develop in three types of 
mature blood cells; red blood cells, blood platelets or granulocytes. Lym-
phoid stem cells develop via lymphoblasts into T-lymphocytes, B-lympho-
cytes or natural killer cells. In ALL too many lymphoblasts, T-lymphocytes 
or B-lymphocytes are produced. These immature cells are not only unable to 
fight infections properly, their large amounts are also displacing the healthy 
blood cells, which may lead to infection, anaemia and blood coagulation dis-
orders [35]. 
The overall incidence rate in Europe of leukaemia in children aged 0-14 
years was 44 per million person-years during 1988-1997. Lymphoid leukae-
mia (LL), which mostly consists of ALL, accounts for around 81 % of leu-
kaemia [36]. Orphanet estimates the prevalence of ALL on 8.1/100,000 [37]. 
There are multiple kinds of prognostic factors that can predict the outcome 
of treatment. Clinical features like age and leukocyte count at diagnosis are 
strong prognostic factors in patients with B-cell precursor ALL. Secondly, 
the genetics of the leukaemia cells play an important part in risk stratifica-
tion. Thirdly, the patient’s pharmacokinetics and pharmacodynamics are of 
influence on treatment response. Early response to treatment, influenced by 
all three features, is consequently the most powerful predictor of outcome. 
The measurement of minimal residual disease, which is the presence of leu-
kaemic cells below the threshold of detection by conventional morphologic 
methods, with the use of either flow cytometry or polymerase-chain-reaction, 
can therefore be an important guide in post-induction treatment [38, 39]. 
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Table 3.2-1: Oncology drugs authorised under exceptional circumstances by the EMA 
International 
Nonproprietary Name Brand Name 
Authorisation 
date Original licenced indication 
Date of regular 
marketing 
authorisation 
docetaxel Taxotere 27.11.1995 Second line monotherapeutic treatment of patients with advanced breast cancer 
after anthracycline failure 
07.07.1998 
alemtuzumab MabCampath 06.07.2001 Treatment of patients with B-cell chronic lymphocytic leukaemia (BCLL) for  
whom fludarabine combination chemotherapy is not appropriate. 
04.07.2008 
temoporfin Foscan 24.10.2001 Palliative treatment of patients with advanced head and neck squamous cell 
carcinoma failing prior therapies and unsuitable for radiotherapy, surgery or 
systemic chemotherapy. 
21.05.2008 
imatinib Glivec 07.11.2001 Adult patients with Philadelphia chromosome (bcr-abl) positive chronic myeloid 
leukaemia (CML) in chronic phase after failure of interferon- alpha therapy, or in 
accelerated phase or myeloid blast crisis 
13.04.2007 
arsenictrioxide Trisenox 05.03.2002 Induction of remission and consolidation in adult patients with relapsed/refractory 
acute promyelocytic leukaemia (APL), characterised by the presence of the t(15;17) 
translocation and/or the presence of the pro-myelocytic leukaemia/retinoic-acid-
receptor alpha (PML/RAR-alpha) gene. Previous treatments hould have included  
a retinoid and chemotherapy. 
10.08.2010 
ibritumomabtiuxetan Zevalin 16.01.2004 Treatment of adult patients with rituximab relapsed or refractory CD20+ follicular 
B-cell non-Hodgkin’s lymphoma (NHL). 
22.05.2008 
bortezomib Velcade 26.04.2004 Treatment of patients with multiple myeloma who have received at least two  
prior therapies and have demonstrated disease progression on the last therapy 
19.03.2012 
clofarabine Evoltra 29.05.2006 Treatment of acute lymphoblastic leukaemia (ALL) in paediatric patients who  
have relapsed or are refractory after receiving at least two prior regimens and 
where there is no other treatment option anticipated to result in a durable response.  
– 
nelarabine Atriance 22.08.2007 Treatment of patients with T-cell acute lymphoblastic leukaemia (T-ALL) and  
T-cell lymphoblastic lymphoma (T-LBL) whose disease has not responded to or  
has relapsed following treatment with at least two chemotherapy regimens. 
– 
trabectedin Yondelis 17.09.2007 Treatment of patients with advanced soft tissue sarcoma, after failure of 
anthracyclines and ifosfamide, or who are unsuited to receive these agents. 
Efficacy data are based mainly on liposarcoma and leiomyosarcoma patients. 
– 
histamine 
dihydrochloride 
Ceplene 07.10.2008 Ceplene maintainance therapy is indicated for adult patients with acute myeloid 
leukaemia in first remission concomitantly treated with interleukin-2 (IL-2). The 
efficacy of Ceplene has not been fully demonstrated in patients older than age 60. 
– 
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Treatment 
Treatment schedules in ALL are adapted to phenotype, genotype and risk of 
the disease subtype. Except for mature B-cell ALL, all subtypes are treated 
with both remission-induction therapy followed by intensification (or consoli-
dation) therapy. Allogeneic hematopoietic stem-cell transplantation (HSCT) 
is not always indicated. Remission-induction therapy aims at reducing the 
amount of leukaemia cells to 1 % or less of the initial burden. It usually con-
sist of three or four different drugs; vincristine, a corticosteroid, L-aspara-
ginase and/or anthracycline [35, 38]. Remission-induction, when successful, 
is followed by treatment intensification. These treatment schedules can largely 
vary between studies and populations, but in childhood ALL high-dose meth-
otrexate, cytarabine, mercaptopurine and high-dose asparaginase are com-
monly used. Maintenance treatment follows for another two to three years, 
consisting usually of weekly methotrexate and daily mercaptopurine, poten-
tially supplemented with other agents.  
To clear leukaemic cells from the central nervous system (CNS) and to pre-
vent CNS-relapse, CNS-directed therapy is given to all patients with ALL. 
This can either exist of intrathecal therapy, CNS-penetrant chemotherapy or 
cranial radiation. CNS-treatment is also adapted to the risk profile of the pa-
tient [35, 38,39]. 
 
Relapse 
Complete remission (CR) is reached in >95 % in children and in 60-80 % in 
adults. Approximately 25-30 % of children relapse or are refractory to initial 
therapy. Relapse within 6 months results in a 10-20 % chance of long-term 
survival, whereas relapse over one year after completion of initial therapy re-
sults in a slightly better outlook with cure rates of 30-40 % [40, 41]. 
Patients in second remission still have a poor outcome and are therefore rec-
ommended for an allogeneic bone marrow transplantation (BMT), stem cell 
transplantation (SCT) or autologous transplantation. For patients in second 
relapse, who would normally have received at least two multi-agent chemo-
therapy regimens, all established treatment options would have been ex-
hausted [41]. 
 
3.2.2 Mechanism of action 
Clofarabine is a nucleoside analogue anti-metabolite anticancer agent. Its 
cytotoxicity results from the inhibition of ribonucleotide reductase and DNA 
polymerase [42]. 
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3.2.3 Summary of licensing documents 
Clofarabine was approved by the EMA on 29 May 2006 for the treatment of 
paediatric patients with relapsed or refractory ALL after receiving at least 
two prior regimens and where there is no other treatment option anticipated 
to result in a durable response.  
 
Efficacy 
The demonstration of efficacy was based on one pivotal phase II study (CLO-
212) [41]. Due to the limited number of patients in second relapse, no exten-
sive clinical development program was conducted. Study CLO-212 was an 
open label, non-randomised, single-arm study in paediatric patients with 
ALL in second or subsequent relapse and/or refractory, who were ≤21 years 
of age at time of initial diagnosis. The primary efficacy endpoint in this 
study was the number of patients to achieve disease remission, categorised 
into complete remission (CR)defined as bone marrow blast counts ≤5 %, no 
evidence of disease and full recovery of peripheral blood counts. CRp was 
defined as complete response without full haematologic recovery and partial 
remission (PR)was defined as complete disappearance of circulating blasts 
and bone marrow blast counts ≤25 %. Overall 61 patients, with a median 
age of 12 years (range 1-20 years) were included in the study. Eighteen out of 
the 61 patients (30 %) achieved a CR, CRp or PR. Twelve 12 of these 18 pa-
tients achieved a CR or CRp (20 %). A total of 10 children underwent HSCT, 
including 8 out of the18 patients who had achieved a response. None of the 
responsive patients had any clofarabine-related or clinically significant tox-
icity that would have prevented HSCT.  
Median survival for all patients was 12.9 weeks and greater than one year for 
patients who had responded to treatment. Although historical data are diffi-
cult to interpret, the EPAR states that data from Dutch and German cancer 
registries indicate that patients with multiply relapsed ALL have an esti-
mated median survival of 9-10 weeks without further intervention.  
 
Safety 
The safety data in the application to the EMA were based on 132 paediatric 
patients (1-21 yrs) with either ALL or acute myeloid leukaemia (AML) who 
took part in one of several phase I or phase II studies [41]. According to the 
EPAR, the interpretation of safety data in uncontrolled studies is difficult 
though, because most patients are heavily pre-treated and might already suf-
fer from on-going toxicity. The most frequently reported drug-related ad-
verse events were nausea (61 %), vomiting (61 %), febrile neutropenia (32 %), 
headache (24 %), pyrexia (21 %), pruritus (21 %) and dermatitis (20 %). Se-
rious adverse events related to treatment with clofarabine were reported in 
58 % of the patients, but only 2 patients discontinued treatment due to an 
adverse event. Four deaths during the trials were considered by the investi-
gators to be related to clofarabine. During the clinical trials with clofara-
bine, six cases of systemic inflammatory response syndrome/capillary leak 
syndrome were reported. Other risks associated with clofarabine are hepatic 
and cardiac toxicity and potentially renal toxicity. Important missing in-
formation is the safety of use for more than 3 cycles.  
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Risk/Benefit 
The scientific discussion of the EPAR states that although an application 
would normally require data generated by randomised, controlled trials, the 
lack of it was justified by the small size of the population of patients in sec-
ond relapse. The facilitating of HSCT by a partial or complete remission was 
considered a meaningful, clinical effect that may have an impact on dura-
tion of survival. The uncertainties regarding the safety profile of clofarabine 
were considered justified in view of the small size of the population of pa-
tients, but additional pharmacovigilance activities were considered neces-
sary.  
 
Specific obligations  
to be fulfilled by the marketing authorisation holder 
Outside of the risk management plan submitted by the manufacturer, the 
CHMP required additional risk minimisation activities in the form of a user’s 
information package, to inform prescribers on the safe use of the drug, and 
the setup and promotion of a voluntary adverse event reporting system [41]. 
During the 3rd annually reassessment, additional obligations have been added 
[43]. The manufacturer was requested to supply population pharmacokinet-
ics data and data to support the recommendation of dose adjustments in pa-
tients with moderate renal impairments. In the monitoring of adverse effects, 
extra attention was to be given to the monitoring of veno-occlusive disease 
after HSCT. 
 
3.2.4 Additional publications 
Table 3.2-3 presents an overview of all published trials and case reports of 
single-agent clofarabine in patients with ALL. A search of the literature 
yielded just five additional publications outside those mentioned in the EPAR, 
two retrospective reports and three case reports. One publication reports of 
five patients in the United Kingdom having been treated with single agent 
clofarabine outside of clinical trials [44]. Two of these 5 patients achieved a 
CR. Single agent therapy was only given during the early study period how-
ever, patients received combination therapy later on. In a retrospective study 
by the Spanish PETHEMA group, 5 of 31 patients were treated with single 
agent clofarabine treatment, 1 achieved a CR [45].  
During the application at the EMA, a second open-label phase II study of 
clofarabine in paediatric patients with refractory/relapsed ALL had already 
started in Europe [41]. The design of the study BIOV-111 was similar to the 
pivotal CLO-212 trial. BIOV-111 had been completed in 2007 and the results 
were presented to the EMA in 2008 and to the FDA in 2010, but have not 
been published. The BIOV-111 results are said to be consistent with the final 
results of CLO-212 [46, 47]. Of 65 paediatric patients included, 3 patients 
(4,6 %) achieved a CR, 12 patients (18,5 %) achieved a CRp and 1 patient 
(1,5 %) achieved a PR. Seven out of 71 treated patients went on to trans-
plant.  
 
 
lack of RCT justified  
by small size of the 
population 
specific obligations 
related to safety 
measures and 
pharmacokinetic data 
 
few reports of  
single-agent use of 
clofarabine 
additional trial 
performed by the 
manufacture has not 
been published 
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Table 3.2-2: Publications on clinical trials and case reports of single-agent use of clofarabine in patients with ALL 
Source Study ID Journal Type of Study 
No. of Patients 
(total/ALL) Age CR+CRi
Barba et al,  
2012 [45] 
 American Journal 
of Hematology 
Retrospective 31 16-72 1/5* 
O’Connor et al, 
2011 [44] 
 British Journal  
of Haematology 
Retrospective 23/5 0-17 2/5* 
McGregor et al, 
2009 [48] 
 Am J Hematol Case Report 3 19-49 2/3 
Johnston et al, 
2008 [49] 
 Pediatric Blood  
& Cancer 
Case Report 1 10 0/1 
Jeha et al,  
2006 [50]# 
CLO-212 J ClinOncol Phase II,  
open-label 
61 1-20 12/61 
(20 %) 
Choi et al,  
2006 [51] 
 Yale J BiolMed Case Report 1 35 1/1 
Jeha et al,  
2004 [52]# 
ID99-383 Blood Phase I,  
dose-finding 
25/17 1-19 7/17 
(41 %) 
Kantarjian et al, 
2003 [53]# 
ID00-038 Blood Phase II,  
open-label 
62/12 19-82 2/12 
(17 %) 
Kantarjian et al, 
2003 [54]# 
DM93-036 J ClinOncol Phase I,  
dose-finding 
51/13 >18 2/13 
(15 %) 
Genzyme  
[46, 47] 
BIOV-111 Unpublished Phase II,  
open-label 
65 <21 15/65 
(23 %) 
# ... Studies included in licencing application  
* .... In both studies, only five patients received single agent treatment. 
 
 
3.2.5 Summary of reimbursement documents 
Clofarabine has been assessed by RIZIV,HAS, CVZ and SMC and received a 
positive recommendation by all four agencies (Table 3.2-3). NICE has not 
assessed clofarabine. The amount of detail in the assessments varies between 
agencies.  
RIZIV (Belgium) presented a very brief summary of efficacy and safety re-
sults from the pivotal trial in their assessment of 1 July 2008 [55]. They ac-
knowledged the absence of alternative treatment for this patient group and 
declared clofarabine eligible for reimbursement. They did however impose 
two additional restrictions; a maximum of three cycles are reimbursed per 
patient and refractory patients have to have tried at least three different regi-
mens before starting clofarabine. 
The Transparency Committee of HAS (France) issued an opinion on clofara-
bine on 13 December 2006 [56]and based its assessment on data from stud-
ies ID00-038 and CLO-212. They concluded that clofarabine significantly 
improves the treatment of ALL in relapsed or refractory children (ASMR II), 
despite the methodological limitations of the pivotal study.  
CVZ (the Netherlands) determined the therapeutic value of clofarabine as 
compared to best supportive care in a report published on 24 September 
2007 [57]. They based the evaluation on the product information and scien-
tific discussion from the EPAR and the published result from studies ID99-
383 [52] and CLO-212 [50]. They concluded that the results of treatment 
with clofarabine, short-term remission in about 25 % of the patients with the 
RIZIV imposes 
restrictions on 
reimbursement 
HAS recommends 
clofarabine for 
reimbursement 
clofarabine is included 
in the Dutch orphan 
drug financing policy 
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possibility long term remission after HSCT, were considerably better than 
the results of best supportive care and therefore clofarabine was recommended 
within its registered indication. It was included in the orphan drug financ-
ing policy. 
SMC (Scotland) issued an advice on 8 December 2006 [58] and adopted the 
opinion of EMA that even though there were no randomised clinical trials, 
the effects of clofarabine in terms of remission and facilitating HSCT were 
considered clinically relevant. The economic analysis presented by the man-
ufacturer however, showed that cost-effectiveness for clofarabine was highly 
dependent on patients receiving HSCT after treatment. The use of clofara-
bine is therefore restricted to patients in whom it is being used to bridge to 
HSC. 
Table 3.2-3: Main remarks on different aspects from the reimbursement evaluations of clofarabine 
 CVZ HAS RIZIV SMC 
Decision date 24.09.2007 13.12.2006 01.07.2008 08.12.2006 
Effectiveness considerable 
better than best 
supportive care 
actual 
benefitis 
substantial 
capable of inducing 
remission 
remission and 
facilitating HSCT 
is clinically 
significant 
Safety often severe side-
effects, sometimes 
life-threatening 
tolerance data 
are limited 
list of AEs in trials important risks 
identified from 
EPAR 
Cost-effectiveness – – – highly dependent 
on HSCT 
Budget impact € 700,000 per year – € 639,180 per year £ 216,000 per year
Severity of disease – – – – 
Easeofuse mentioned – mentioned – 
Recommended yes yes yes yes 
Conditions evidence 
development 
 max 3 cycles, 
refractory patients 
after 3 prior regimens 
only as a bridge  
to HSCT 
Abbreviations: CVZ – College voor Zorgverzekeringen, HAS – Haute Autorité de Santé, RIZIV – Rijks Instituut voor Ziekte- en 
Invaliditeits Verzekering, SMC – Scottish Medicines Consortium, AE – adverse event, HSCT – Hematopoietic stem cell 
transplant, EPAR – European public assessment report 
 
 
 
3.3 Nelarabine – Atriance 
3.3.1 Indication 
Lymphoblastic leukaemia (LBL) is considered the lymphomatous variant of 
ALL (see chapter Clofarabine). The abnormal lymphocytes are generally in 
the lymph nodes or thymus gland and the bone marrow is lesser involved 
(<25 % marrow blasts). LBL is a form of non-Hodgkin lymphoma, a large 
group of cancers of lymphocytes. Treatment strategies for T-ALL and T-LBL 
are often the same, with comparable results [35, 59]. 
 
SMC restricts 
clofarabine to patients 
that are eligible  
for HSCT 
 
lymphoblastic 
leukaemia is considered 
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variant of ALL 
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3.3.2 Mechanism of action 
Nelarabine is the water soluble prodrug of 9-beta-D-arabinofuranosyl gua-
nine (ara-G), an antineoplastic agent that acts as DNA synthesis inhibitor. 
Ara-G is converted intracellularly to the active triphosphate ara-GTP, in 
both B-cells and T-cells. Due to a more rapid catabolism in B-cells, ara-G is 
selectively toxic to T-cells owing to a greater exposure to ara-GTP [60]. 
 
3.3.3 Summary of licensing documents 
Nelarabine received its marketing authorisation under exceptional circum-
stances on 22 August 2007. It is indicated for the treatment of patients with 
T-cell acute lymphoblastic leukaemia (T-ALL) and T-cell lymphoblastic lym-
phoma (T-LBL) whose disease has not responded to or has relapsed follow-
ing treatment with at least two chemotherapy regimens.  
 
Efficacy 
In the application to EMA, the applicant presented two pivotal phase II open-
label studies, one in patients ≥16 years of age (Study ID PGAA2002) and 
one in patients ≤21 years of age (Study ID PGAA2001) [61].  
Study PGAA2001 was a phase II, open-label, multicentre clinical trial which 
included paediatric patient ≤21 years of age at diagnosis with refractory or 
recurrent T-ALL or T-LBL. Nelarabine was administered at a dose ranging 
from 400 mg/m2 to 1200 mg/m2 as a one-hour infusion daily over five days, 
every three weeks. The objectives of the study were to evaluate the response 
rate i.e. complete response (CR) defined as bone marrow blast counts ≤5 %, 
no evidence of disease and full recovery of peripheral blood counts. CR* was 
defined as complete response without full haematologic recovery. Partial re-
sponse (PR) was defined as bone marrow blast ≤25 %. Secondary outcome 
measures included duration of response and overall survival. Five out of 39 
patients in second relapse achieved a CR and an additional four patients 
achieved a CR*. The median duration of response was 12,3 weeks. Four of 
the nine patients in CR or CR* received an SCT. The median overall sur-
vival in patients in second relapse was thirteen weeks and the one-year sur-
vival was 14 %.  
Study PGAA2002 was a similar study in adult patients ≥16 years of age with 
relapsed or refractory T-ALL or T-LBL. Nelarabine was administered at a 
dosage of 1500 mg/m2 i.v. over 2 hours on days 1, 3, and 5 of a 21 day cycle. 
Objectives and outcomes were similar to study PGAA2001. Five out of 28 pa-
tients with two or more prior inductions achieved a CR and one additional 
patient received a CR*. The duration of response in patients in second re-
lapse ranged from four to 195,4+ weeks. The median overall survival was 
20,6 weeks and the one-year survival 29 %.  
 
Safety 
The safety evaluation in the EPAR was based on 459 adult and paediatric 
patients enrolled in four phase I studies and three phase II studies. Neuro-
logical toxicity was the dose-limiting toxicity and despite of an extensive 
phase I programme, early in the pivotal phase II trials additional dose-adjust-
ments had to be made. In adult patients receiving the adjusted 1500 mg/m2 
antineoplastic agent  
and DNA synthesis 
inhibitor 
two pivotal  
phase II studies 
one trial in adult 
patients and one trial  
in paediatric patients 
safety data based  
on 459 patients 
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dose, the safety profile in terms of haematological and gastrointestinal ef-
fects was comparable to other cytotoxic agents. Neurological adverse events 
were reported in 8 % of the adult patients involved in phase II studies com-
pared with 20 % in paediatric patients that received 650 mg/m2. Ninety-nine 
per cent of the paediatric patients in this dose group experienced haemato-
logical toxicities. Among all the patients in the database, 13 % experienced a 
grade 3 neurological adverse event and 7 % a grade 4 neurological adverse 
event. The limited safety database resulted in specific post-marketing obli-
gations.  
 
Risk/Benefit 
The EPAR states that although normally an application would require data 
generated by randomised, controlled trials, the lack of it was justified by the 
small size of the population of patients in second relapse. And even though 
it was not possible to compare the response rate with anything, the magni-
tude was deemed clinically relevant because some patients were able to un-
dergo a stem cell transplant. The uncertainties regarding the safety profile of 
nelarabine were considered justified in view of the small size of the popula-
tion of patients, but additional pharmacovigilance activities were necessary.  
 
Specific obligations  
to be fulfilled by the marketing authorisation holder 
The CHMP required the following specific obligations: 
b To provide data from an on-going phase III Children’s Oncology 
Group study AALL0434, entitled “intensified methotrexate, nelara-
bine and augmented Berlin-Frankfurt-Münster therapy for children 
and young adults with newly diagnosed T-cell ac ute lymphoblastic 
leukaemia”. 
b To perform a post-marketing surveillance study for nelarabine in the 
indicated patient population under 21 years of age receiving the 650 mg/ 
m2 dose [62]. 
 
3.3.4 Additional publications 
Table 3.3-1 presents an overview of all published trials and case reports of 
single-agent nelarabine in patients with ALL. A search of the literature 
yielded just six additional publications outside those mentioned in the EPAR, 
two clinical trials and four case reports. Two of the publications were in Ja-
panese and could not be understood.  
The single arm trial by Gökbuget et al [63]included thirteen patients in sec-
ond relapse and reported a response rate of six complete remissions with or 
without full haematologic recovery. One-year survival however, was only 
9 %. Information from clinicaltrials.gov indicates that nelarabine is currently 
being tested in several multi-agent regimens, in different clinical trials. 
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population 
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two additional 
clinicaltrialspublished 
Results 
LBI-HTA | 2013 31 
Table 3.3-1: Publications on clinical trials and case reports of single-agent use of nelarabine in patients with ALL 
Source Study ID Journal 
Type  
of Study  
No. of  
Patients 
Age median 
(range) 
CR+Cri 
[95 %CI] 
Go¨kbuget et al, 
2011 [63] 
 J Clin Oncol Phase II, 
single arm 
Total=126 2nd 
relapse=13 
33  
(18-81) 
CR 6/13 (46 %)
Horibe et al, 
2011 [64] 
PGA105446 Rinsho 
Ketsueki 
Phase I    
Papayannidis  
et al, 2010 [65] 
 Am J 
Hematol 
Case report 1 30 CR, complete 
paraplegia 
Iino et al, 
2009 [66] 
 Rinsho 
Ketsueki 
Case report    
Sigalas et al, 
2009 [67] 
 Leuk Res Case report 1 31 CR 
Alvarado et al, 
2007 [68] 
 Leuk Res Case report 1 48 CR 
DeAngelo et al, 
2007 [69]# 
PGAA2002 Blood Phase II, 
single arm 
Total=39,  
2nd relapse=28 
34  
(16-66) 
29 %  
[13 %, 49 %] 
Berg et al, 
2005 [70]# 
PGAA2001 J Clin Oncol Phase II, 
single arm 
Total=153,  
2nd relapse=39*
10.8  
(2.5-20) 
23 %  
[11 %, 39 %] 
Kurtzberg et al, 
2005 [71]# 
PGAA1001 J Clin Oncol Phase I,  
dose finding
Total=93,  
T-ALL/LBL=39 
(3-75) CR 9/39 (23 %) 
# ... Studies included in licencing application  
 
 
3.3.5 Summary of reimbursement documents 
Nelarabine has been assessed by HAS, RIZIV and SMC and all three have 
recommended nelarabine for reimbursement (Table 3.3-2).  
In the decision document from 1 June 2008 [72], RIZIV presented a brief 
overview of the results from the pivotal study, the incidence of ALL/LBL in 
Belgium and an estimation of the budget impact. In their re-evaluation in 
November 2010, it became clear that there was hardly any new information 
available. To that date, only one patient per year had been treated with ne-
larabine in Belgium.  
The Transparency Committee of HAS issued an opinion on nelarabine on 19 
December 2007 [73]. In their report they present a brief overview of the clin-
ical efficacy and safety data from the two pivotal trials. They considered the 
efficacy/safety ratio of this product to be high and recognised the lack of al-
ternative treatments in adult patients. Nelarabine was considered to provide 
a significant improvement in actual benefit (ASMR II), by facilitating access 
to an allograft in some patients. Therefore, nelarabine was recommended 
for reimbursement.  
In their recommendation of 7 March 2008 SMC adopted the opinion of the 
EMA that the lack of randomised trials was justified in view of the small size 
of the population of patients in second relapse [74]. Additionally they ac-
cepted the complete response rate as a reasonable surrogate for clinical bene-
fit. They deemed the economic analysis provided by the manufacturer to be 
of good quality, but cost-effectiveness was highly depending on HSCT and 
the assumed prolonged survival after that procedure. Therefore the SMC ac-
cepted the use of nelarabine only as a treatment to bridge to HSCT and not 
for palliation.  
RIZIV recommends 
nelarabine 
HAS emphasises the 
significant improvement 
in actual benefit 
SMC restricts nelarabine 
to patients that are 
eligible for HSCT 
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Nelarabine was not evaluated by NICE. It was considered for a potential 
technology appraisal, but rejected in July 2007 [75]. CVZ also did not evalu-
ate nelarabine, because it was expected that the costs would not reach the 
threshold for additional funding. 
Table 3.3-2: Main remarks on different aspects from the reimbursement evaluations of nelarabine 
 HAS RIZIV SMC 
Date 19.12.2007 01.06.2008 07.03.2008 
Effectiveness significant improvement 
in actual benefit 
presented main efficacy 
results 
meaningful response rates 
Safety few safety data presented main AEs  presented main AEs 
Cost-effectiveness – – highly dependent on HSCT 
Budget impact – max. € 510,134 per year less than £ 107,000 per year 
Severity of disease – – – 
Easeofuse – – – 
Recommended yes yes yes 
Conditions   only to as a bridge to HSCT 
Abbreviations: HAS – Haute Autorité de Santé, RIZIV – RijksInstituut voor Ziekte- en InvaliditeitsVerzekering,  
SMC – Scottish Medicines Consortium, AE – adverse event, HSCT – Hematopoietic stem cell transplant 
 
 
3.4 Trabectedin – Yondelis 
3.4.1 Indication 
Soft tissue sarcoma (STS) is a cancer that begins in the muscle, fat, fibrous 
tissue, blood vessels, or other supporting tissue of the body [76]. The World 
Health Organization has defined more than 50 histological subtypes [77]. The 
prevalence of STS in Europe is estimated at 23.7/100,000 [37]. STS is diag-
nosed by means of a biopsy for microscopic examination to determine the 
histologic type and tumour grade. Morphologic diagnosis is often comple-
mented by ancillary techniques like immunohistochemistry, classical cytoge-
netics, electron microscopy and molecular genetic testing [78]. Prognostic fac-
tors in STS are the patient’s age and the size, histologic grade, mitotic activity, 
and stage of the tumour [76]. 
 
Treatment 
Factors of influence on STS treatment are the site of the tumour (e.g. head 
and neck, trunk, extremities) and stage of the tumour, for which multiple 
systems are used. The main treatment for localised disease is surgery. Surgi-
cal margins in STS are classified as intralaesional, marginal, wide and radi-
cal. Radiotherapy is applied in intermediate or high grade STS, large deep 
low grade sarcomas and incompletely resected tumours that are close to im-
portant structures [77]. Radiation therapy can be administered as primary 
therapy, preoperatively or postoperatively [78]. Chemotherapy is used in high 
grade tumours to shrink the tumour before surgery. Postoperatively it can 
increase relapse-free-survival. For advanced, unresectable or metastatic dis-
ease several regimens are available [78]. 
nelarabine was not 
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3.4.2 Mechanism of action 
Trabectedin was initially obtained by isolation from the marine tunicate Ec-
teiniascidia turbinate, nowadays it is produced synthetically. Trabectedin pre-
dominantly binds to the minor groove of DNA and thereby delaying S-phase 
progression and inducing G2/M arrest. The precise mechanism of action how-
ever, is not completely understood [79]. 
 
3.4.3 Summary of licensing documents 
Trabectedin was authorised by the EMA on 17 September 2007, for the treat-
ment of patients with advanced STS, after failure of anthracyclines and ifos-
famide, or who are unsuited to receive these agents. Efficacy data are based 
mainly on liposarcoma and leiomyosarcoma patients. An application for Mar-
keting Authorisation submitted in November 2001 had previously been re-
jected [80].  
 
Efficacy 
In the first application, four phase I studies in patients with solid tumours 
were provided. In the second application an additional phase I study and a 
randomised, multi-centre, open-label study of trabectedin administered in 
two different schedules in patients with metastatic liposarcoma or leiomyo-
sarcoma following treatment with an anthracycline and ifosfamide (ET743-
STS-201) were submitted.  
This pivotal study ET743-STS-201was originally designed to select the most 
appropriate dosing schedule for further testing. After preliminary descriptive 
data suggested that one of the two treatment schedules would be more effi-
cacious, the study was extended and the protocol amended, to allow for a di-
rect comparison between treatment schedules. Information on the inclusion 
criteria and the intervention is missing from the EPAR but can be found in 
the article by Demetri et al, 2009 [81]. After the protocol amendment, pa-
tients were randomly assigned to one of two treatment schedules; trabecte-
din 1,5mg/m2 in a 24-h infusion once every three weeks (q3wk 24-h) or tra-
bectedin 0,58mg/m2 in a 3-h infusion weekly every three out of four weeks 
(qwk 3-h). Crossover to the alternative treatment schedule was allowed after 
progressive disease. After the protocol amendment, the primary endpoint was 
changed to time to progression (TTP), calculated as the time between date of 
randomisation and date of disease progression. Secondary endpoints were 
overall objective response, progression-free survival and overall survival. 
Eligibility criteria included ≥18 years of age, histological confirmation of 
liposarcoma or leiomyosarcoma, unresectable and/or metastatic disease and 
prior treatment with at least an anthracycline and ifosfamide (combined or 
sequential). Tumours were assessed every eight weeks by a blinded independ-
ent review of diagnostic imaging by two radiologists, with a third radiologist 
resolving discrepancies [81].  
At the time of the application to EMA, 266 patients had been randomly as-
signed to a treatment arm and were included in the primary analysis. The 
two study groups were well balanced for both demographic characteristic as 
well as prognostic variables. Time to progression at the primary analysis was 
2.1 months (95 %CI 1.9-3.6) for the qwk 3-h treatment arm and 3.8 months 
(95 % CI 2.1-5.4) for the q3wk 24-h treatment arm. Although not statistically 
precise mechanism  
is not completely 
understood 
on pivotal, double arm, 
uncontrolled, phase II 
study, 266 patients 
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significant, consistent trends were seen for PFS and OS. An updated report 
including new statistical analyses showed statistically significant results on 
the primary endpoint TTP. An additional survival analysis was requested by 
the CHMP. No statistically significant difference in survival was shown, but 
this might be due to crossover between treatment arms. 
Table 3.4-1: Main outcomes of study ET743-STS-201 
Primary analysis q3wk 24-h qwk 3-h 
 n=132 n=134 
TTP, median months [95 %CI] 3.8 [2.1-5.4] 2.1 [1.9-3.6] 
PFS, median months [95 %CI] 3.5 [2.0-4.5] 2.1 [1.9-3.4] 
OS, median months [95 %CI] 16.7 [12.2-n.r.] 11.8 [8.9-14.9] 
Ancillary analysis q3wk 24-h qwk 3-h 
 n=136 n=134 
TTP, median months [95 %CI] 3.7 [2.1-5.4] 2.3 [2.0-3.5] 
TTP – Time to progression, PFS – Progression free survival, OS – overall survival 
 
Safety 
After the last update, the assessment of safety was based on data from clini-
cal trials in 569 patients treated with the recommended regimen in several 
cancer types. Approximately 91 % of the patients experienced any type of 
adverse event and around 40 % experienced a grade 3 or 4 adverse event. 
Most common adverse reactions were nausea, fatigue, vomiting, anorexia, 
neutropenia and increases in AST/ALT. Fatal adverse reactions have occurred 
in 1,9 %. Cumulative toxicity has not been observed [80].  
 
Risk/Benefit 
The EPAR states that trabectedin should ideally have been compared in an 
adequately designed and analysed randomised trial to best care or investiga-
tor’s choice. This was not possible due to the absence of a control arm in the 
pivotal study. The applicant claimed that a comparison to best supportive 
care is considered very difficult in this patient population. The population 
of STS patients was considered heterogeneous and individual subpopula-
tions are considered too rare for adequately powered randomised controlled 
trials to be conducted against best supportive care to explore factors associ-
ated with response to treatment within reasonable time. Conclusively, due to 
the rarity of the disease, the CHMP decided by consensus that the risk/benefit 
ratio of trabectedin was favourable and that the marketing authorisation 
could be granted under exceptional circumstances. Routine pharmacovigi-
lance was considered adequate to monitor the safety of the product.  
 
Specific obligations  
to be fulfilled by the marketing authorisation holder 
Because the authorisation was an approval under exceptional circumstances, 
the marketing authorisation holder had to conduct a further investigation in 
order to elucidate whether predictorsof response to trabectedin in patients 
with STS could beidentified. The final study report should have been sub-
mitted by 30 June 2012 [82]. This report is still awaited [83].  
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3.4.4 Additional publications 
A search after additional published material of single-agent use of trabecte-
din in STS resulted in 25 articles of phase II clinical trials, retrospective case 
series analyses and case reports (Table 3.4-2). The retrospective case series 
analyses mostly included patients in compassionate use programmes.  
Table 3.4-2: Publications of single-agent use of trabectedin in patients with soft tissue sarcoma 
Source Journal Type of Study No. ofPts Subtype 
Paz-Ares et al, 
2012 [84] 
Invest New 
Drugs 
Phase II, 
uncontrolled 
41 advanced or metastatis STS 
Gronchi et al, 
2012 [85] 
Ann Oncol Phase II, 
uncontrolled 
29 myxoid liposarcoma,  
non-metastatic 
Baruchel et al, 
2012 [86] 
Eur J Cancer Phase II, 
uncontrolled 
50 relapsed pediatric sarcomas 
Monk et al,  
2012 [87] 
Gynecol 
Oncol 
Phase II, 
uncontrolled 
20 uterine leiomyosarcoma 
Scho¨ffski et al, 
2012 [88] 
Onkologie Phase II, 
uncontrolled 
28 STS 
Sanfilippo et al, 
2011[89] 
Gynecol 
Oncol 
Retrospective case 
series analysis 
66 metastatic uterine 
leiomyosarcoma 
Corrado et al, 
2011 [90] 
Gynecol 
Oncol 
Case report 1 advanced uterine 
leiomyosarcoma 
Schmitt et al, 
2010 [91] 
Mar Drugs Retrospective case 
series analysis 
25 STS excluded Ewing’s and 
osteosarcoma 
Fayette et al, 
2010 [92] 
Anticancer 
Drugs 
Retrospective case 
series analysis 
92 STS 
Demetri et al, 
2009 [81] 
J Clin Oncol Phase II, secondline 270 advanced or metastatic 
liposarcoma or leiomyosarcoma 
Grosso et al, 
2009 [93] 
Ann Oncol Retrospective case 
series analysis 
32 myxoid liposarcoma 
Amant et al, 
2009 [94] 
Int J Gynecol 
Cancer 
Case report 5 uterine leiomyosarcoma 
Roylance et al, 
2007 [95] 
Clin Oncol  
(R Coll Radiol) 
Observational study 21 pre-treated advanced sarcoma 
Grosso et al, 
2007 [96] 
Lancet Oncol Retrospective case 
series analysis 
51 myxoid liposarcoma 
Tewari et al, 
2006 [97] 
Gynecol 
Oncol 
Case report 1 metastatic uterine 
leiomyosarcoma 
Garcia-Carbonero 
et al, 2005 [98] 
J Clin Oncol Phase II, first line 36 advanced STS 
Therasse et al, 
2005 [99] 
Eur J Cancer Phase II,  
non-randomised 
49 advanced STS 
Le Cesne et al, 
2005 [100] 
J Clin Oncol Phase II,  
non-randomised 
104 advanced STS 
Blay et al, 
2004[101] 
Eur J Cancer Phase II,  
non-randomised 
28 advanced GIST 
Garcia-Carbonero 
et al, 2004 [102] 
J Clin Oncol Phase II,  
non-randomised 
36 advanced STS 
Yovine et al, 
2004 [103] 
J Clin Oncol Phase II,  
non-randomised 
54 advanced STS 
Laverdiere et al, 
2003 [104] 
Cancer Phase II,  
non-randomised 
25 osteosarcoma 
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Source Journal Type of Study No. ofPts Subtype 
Demetri et al, 
2002 [105] 
Anticancer 
Drugs 
Phase II,  
non-randomised 
72 metastatic or advanced STS 
Brain et al,  
2002 [106] 
Anticancer 
Drugs 
Phase II,  
non-randomised 
54 advanced pretreated STS 
Delaloge et al, 
2001 [107] 
J Clin Oncol Retrospective 29 sarcoma 
 
 
3.4.5 Summary of reimbursement documents 
Trabectedin was evaluated by all five agencies. The SMC was the only agen-
cy that did not recommend trabectedin (Table 3.4-3). 
In the decision document from 13 November 2008, RIZIV presents a brief 
overview of the results from the pivotal study, contra-indications and ease of 
use, the incidence of STS in Belgium and an estimation of the budget impact. 
Because trabectedin has orphan status, an economic evaluation is not neces-
sary.  
The NICE Guidance for trabectedin in the treatment of STS was published 
on 1 February 2010. Trabectedin was recommended with a patient access 
scheme, in which it is agreed that the acquisition costs of trabectedin for 
treatment needed after the fifth cycle are met by the manufacturer.  
The clinical evidence submitted by the manufacturer included the pivotal 
trial and three additional uncontrolledphase II trials. As there were no con-
trolled studies, historical control data from studies in the European Organi-
sation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma 
Group (EORTC STBSG) database were used to approximate best supportive 
care (BSC). The Committee concluded this to be appropriate for this disease 
area. They noted that the median overall survival and progression free sur-
vival for patients on the licenced dosage of trabectedin, exceeded that for pa-
tients receiving BSC, therefore they concluded that trabectedin was a clini-
cally effective treatment.  
In the guidance a lot of attention is given to the determination of the ICER, 
which is eventually estimated at £ 34,500 per QALY gained, with inclusion 
of the patient access scheme.  
HAS published a report on trabectedin on 02 April 2008 and based their as-
sessment on the pivotal study from the EPAR. Due to the lack of data from 
studies versus “supportive care” or a formalised comparison with a historic 
cohort, they concluded that trabectedin offers no improvement in actual 
benefit (level V). They do however recommend it for inclusion on the list of 
medicines approved foruse by hospitals and various public services. 
After an application by the manufacturer for reimbursement, CVZ issued a 
report on 28 April 2008 which did not recommend trabectedin for outpatient 
use [108]. It concluded that trabectedin as a second line therapy in leiomyo- 
and myxoid liposarcoma appeared efficacious, but that the sometimes severe, 
acute and deadly adverse effects make it unsuitable for outpatient use. In 
October 2009 the Dutch Federation for University Medical Centres applied 
for inclusion in the Orphan Drug policy, which was followed by a positive 
recommendation by CVZ on 22 February 2010 [109]. In this assessment, be-
sides the EPAR, four additional studies were included (Yovine et al, Garcia-
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recommended with a 
patient access scheme 
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Carbonero et al, 2004, Le Cesne et al, Roylance et al, Table 3.4-2). Due to the 
lack of randomised, controlled trials, they conclude that trabectedin appears 
to be efficacious and that it may be possible to increase the period of stable 
disease. An increase in overall survival has however not been proven. As re-
quired by the Orphan Drug policy, additional cost-effectiveness research is 
now being performed [110].  
The evaluation by SMC from 11 August 2008 emphasised the limited efficacy 
data. The lack of comparisons with best supportive care or other therapy made 
it difficult to evaluate the additional clinical benefit. The cost-effectiveness 
evaluation submitted by the manufacturer was deemed unreliable. Where 
the manufacturer estimated the ICER to be £ 29,954 per QALY, the SMC had 
great doubts about the quality of the economic analysis and estimates the 
ICER to be at least £ 40,000. As a result, trabectedin is not recommended [111].  
Table 3.4-3: Main remarks on different aspects from the reimbursement evaluations of trabectedin 
 CVZ HAS NICE RIZIV SMC 
Date 22.02.2010 02.04.2008 01.02.2010 01.02.2009 11.01.2008 
Effectiveness appears to 
be effective 
activity is 
minor and 
difficult to 
evaluate 
clinically 
effective 
presented 
main efficacy 
results 
difficult to evaluate 
additional clinical 
benefit over 
standard practice 
Safety sometimes 
severe and 
fatal 
mainly 
haematological 
and hepatic 
toxicity 
most AEs 
reversible and 
non-cumulative 
presented 
main AEs 
presented main 
AEs and comments 
from EPAR 
Cost-
effectiveness 
  £ 34,500 per 
QALY 
 around £ 40,000 
or higher 
Budget impact € 5.3 million 
per year 
  € 242.798 a` 
€ 353.161 per 
year 
£ 243,000 in year 1 
rising to £ 289,000 
by year 5 
Ease of use IV infusion   central venous 
catheter 
 
Recommended Yes Yes Yes* Yes No 
* With patient access scheme 
Abbreviations: CVZ – College voor Zorgverzekeringen, HAS – Haute Autorité de Santé, NICE – National Institute for Health 
and Clinical Excellence, RIZIV – Rijks Instituut voor Ziekte- en InvaliditeitsVerzekering, SMC – Scottish Medicines Consortium, 
AE – adverse event, EPAR – European public assessment report, QALY – Quality adjusted life-year 
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3.5 Ceplene – histamine dihydrochloride 
3.5.1 Indication 
Acute myeloid leukaemia (AML) is a cancer of blood or bone marrow cells 
from the myeloid lineage (See chapter clofarabine). In 2008 the AML-sub-
types were reclassified under WHO supervision and now incorporate and in-
terrelate morphology, cytogenetics, molecular genetics, and immunologic mark-
ers [112]. The older French-American-British (FAB) criteria relied solely on 
morphologic features [113]. Like in ALL, the leukaemia cells displace the 
healthy blood cells, which may lead to infection, anaemia and blood coagula-
tion disorders. The estimated prevalence of AML in Europe is 16/100,000 [37]. 
Prognostic factors in AML can be divided into patient characteristics, like 
age and general health condition, and leukaemia cell characteristics, like the 
karyotype of the cells and the molecular genetics. The monitoring of minimal 
residual disease is also in AML a tool to improve risk stratification [112]. 
 
Treatment 
Treatment strategies in AML differ from ALL strategies. AML treatment simi-
larly starts with remission induction and is followed by postremission ther-
apy. CNS prophylactic therapy and maintenance treatment however, are usu-
ally not indicated [112, 114]. The current standard for remission induction 
therapy is three days of an anthracycline (daunorubicin or idarubicin) or mi-
toxantrone, followed by seven days of cytarabine. CR is achieved in 60 % to 
80 % of younger adults. There are multiple possibilities in postremission ther-
apy, and in certain subtypes of AML some strategies have proven to be supe-
rior to others. High-dose cytarabine has improved outcome in patients with 
certain cytogenetic abnormalities. Autologous HSCT is an alternative for 
post-remission therapy in patients with favourable or intermediate risk cy-
togenetics. Allogeneic HSCT is associated with the lowest risk of relapse. This 
is attributed to both the high-dose regimen of the conditioning treatment and 
the graft-versus-leukaemia effect. Treatment related mortality limits the bene-
fits unfortunately; therefore the risks associated with the transplant itself, e.g. 
comorbidities, should be an important factor in clinical decision making [112]. 
 
3.5.2 Mechanism of action 
Histamine dihydrochloride (HDC) is a synthetic immune modulator, indi-
cated for maintenance therapy for adult patients with AML in first remis-
sion concomitantly treated with interleukin-2 (IL-2). IL-2 is deployed to ac-
tivate natural killer cells and T-lymphocytes that kill tumour cells. IL-2 has 
been administrated to patients to prevent relapse in several randomised and 
non-randomised trials, but the result were inconsistent and failed to demon-
strate a reduced frequency of relapse. The addition of HDC to improve the 
function of cytotoxic lymphocytes was based on in vitro and in vivo studies in 
multiple human malignant target cells and a phase II pilot study suggested 
it to be safe and feasible [115]. 
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3.5.3 Summary of licensing documents 
The application for marketing authorisation for Ceplene was submitted on 
06 October 2006. After an initial refusal and re-examination by the EMA it 
was approved on 07 October 2008 as maintenance therapy indicated for 
adult patients with acute myeloid leukaemia in first remission, concomitantly 
treated with IL-2 [116].  
 
Efficacy 
The pivotal trial, study MP-MA-0201, was a randomised, open label, multi-
center phase III trial with the main goal to compare the effect of HDC/IL-2 
therapy versus no treatment on leukaemia free survival (LFS) in patients 
with acute myeloid leukaemia in complete remission. Three hundred twenty 
patients were included in the study and randomisation was stratified based 
on first or subsequent remission. The study showed a statistically significant 
difference in LFS in the population in first remission. Kaplan-Meier estimates 
of 3-year LFS were 26 % in the control group and 40 % in the HDC/IL-2 
group (p=0,02). No significant differences were observed in the population 
in subsequent remission or in overall survival, but it should be noted that 
the study was not sufficiently powered for the latter [115, 116].  
 
Safety 
A total of 1,188 patients were treated with HDC and 689 control patients were 
part of the clinical development program. The most common adverse effects 
were flushing, hypotension, headache and injection site reactions. No study 
medication related deaths were reported. Quality-of-life levels were similar 
in both treatment groups [116].  
 
Risk/Benefit 
After an oral explanation by the applicant to the CHMP, to address the out-
standing issues, the CHMP decided that the risk-benefit balance for Ceplene 
was unfavourable. The main reason for this decision was the dependence on 
one pivotal study [116]. In document CPMP/EWP/2330/99 the EMA states 
that there is no formal requirement to include two or more pivotal studies, 
but in the exceptional event of a submission with only one pivotal study, this 
has to be particularly compelling with respect to internal and external valid-
ity, clinical relevance, statistical significance, data quality and internal con-
sistency [117]. In the case of Ceplene, the CHMP considered the requirements 
of statistically compelling results not to be fulfilled. There was also only one 
supportive clinical phase II study available in only 39 patients. Thirdly, the 
pharmacological rationale was deemed to be weak and the supporting non-
clinical data were not considered to be sufficient [116].  
After the initial recommendation, the applicant provided detailed grounds 
for re-examination including the opinion of expert European biostatiticians 
to support the pivotal trial and a review of the pharmacological rationale. For 
the re-examination of Ceplene, the CHMP consulted a scientific advisory 
group (SAG) in oncology to obtain advice on different matters relating to the 
clinical efficacy. There were different views on the robustness of the efficacy 
data and the support of the pharmacological rationale within the SAG. Some 
considered the single pivotal trial not to provide conclusive evidence due to 
marked heterogeneity between participating countries/centres, insufficient 
pivotal, controlled, 
phase III trial 
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support of pharmacological rationale, non-clinical data provided, absence of 
proof of concept in eradication minimal residual disease and finally the 
negative outcome of the clinical trials with HDC/IL-2 in other indications. 
Others considered the biological rationale to be sound and found the uncer-
tainty of the individual effects of the combination less important and con-
sidered the combination showed efficacy for a clinically relevant endpoint in 
a condition where there is a high medical need. Combined with the manage-
able toxicity, the benefits were considered important, even in the absence of 
extensive supportive data [116].  
After reconsideration the CHMP concluded that the pivotal study could be 
considered as exceptionally compelling, particularly due to the high quality 
of the conduct of the study, the clinically and statistically significant results, 
and the internal validity. Also, the pharmacological rationale was accepted. 
HDC was approved by majority decision. Further clinical data were however 
requested [116].  
 
Specific obligations  
to be fulfilled by the marketing authorisation holder 
The marketing authorisation holder has to complete two post-authorisation 
obligations. 
b A clinical study to evaluate the biomarkers and pharmacologic end-
points of Ceplene plus low dose interleukin-2 in approximately 100 
adult patients stratified by age greater or less than 60 years with acute 
myeloid leukemia in first complete remission (CR), with well charac-
terized morphologic, cytogenetic and molecular profiles, to be com-
pleted in the second quarter of 2013. 
b A clinical study to evaluate minimal residual disease for the assess-
ment of the anti-leukaemic activity of Ceplene plus low dose inter-
leukin-2 in approximately 150 adult patients stratified by age greater 
or less than 60 years with acute myeloid leukemia in first complete 
remission, to be completed in the second quarter of 2013 [118]. 
 
3.5.4 Additional publications 
Since the marketing authorisation in October 2008, only one additional 
clinical study has been performed. According to the information from clini-
caltrials.gov, the final data collection for the primary outcome measures 
should have been completed in August 2012. There are no additional publi-
cations for HDC in AML.  
 
3.5.5 Summary of reimbursement documents 
To date, only HAS, CVZ and SMC have issued a recommendation on Ce-
plene; HAS a positive one, CVZ and SMC a negative (Table 3.5-1).  
The HAS report from 1 December 2010 briefly mentioned the methodologi-
cal shortcomings of pivotal trial, but also recognised the absence of alterna-
tive maintenance treatments for AML patients and therefore gave a positive 
advice for the use of HDC in AML patients under 60 years in first remission 
that are ineligible for an allograft.  
HDC was approved by 
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concerned two 
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there are no additional 
publication for HDC  
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HAS recommends HDC 
inspite of shortcomings 
of pivotal trial 
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CVZ released the most extensive evaluation of HDC on 26 September 2011, 
about three years after the marketing authorisation. In the evaluation a lot of 
attention was given to the methodological shortcomings of study MP-MA-0201 
and consequentially they concluded that the positive effects of HDC (five-
month gain in leukaemia free survival, no significant difference in overall 
survival) were insufficiently supported. An important shortcoming was the 
absence of information on induction therapies and the great heterogeneity 
that could be expected in these induction therapies. Additionally the differ-
ence in effect on LFS between different countries, showed that the standard 
of care in a specific country was of influence on the LFS. Together with the 
fact that the study was performed between 1998 and 2002, this meant that 
there is great uncertainty if the chemotherapy received by patients in the 
study, corresponded with current practice.  
The SMC advice from 17 December 2010 is less extensive. Their main issues 
in the assessment of effectiveness were the lack of data on prior induction and 
consolidation regimens and on subsequent treatments following relapse, mak-
ing the interpretation of the OS data problematic. Additionally, clinical ex-
perts indicated that the standard of care in AML had improved since the 
pivotal study was performed, hence HDC’s potential place in therapy was 
unclear. The SMC also evaluated a cost-utility analysis submitted by the 
manufacturer and judged it to be insufficiently robust.  
Table 3.5-1: Main remarks on different aspects from the reimbursement evaluations of histamine dihydrochloride 
 CVZ HAS SMC 
Date 26.09.2011 01.12.2010 17.12.2010 
Effectiveness insufficient evidence methodological weaknesses considerable uncertainty 
Safety no fatal AEs thrombocytopenia most 
serious AE 
no fatal AEs 
Cost-effectiveness – – considerable uncertainty 
Budget impact – – up to £ 1,2m per year 
Severity of disease – serious, life-threatening – 
Ease of use self-administrable – – 
Recommended no yes no 
Abbrevations: CVZ – College voor Zorgverzekeringen, HAS – Haute Autorité de Santé, SMC – Scottish Medicines Consortium, 
AE – adverse event 
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4 Discussion 
This report aims to provide insight into the authorisation under exceptional 
circumstances of oncology drugs. Since the founding of the EMA in 1995, 
eleven oncologic drugs have been authorised under exceptional circumstances, 
seven of which received a regular marketing authorisation later on. The four 
drugs that are still licenced under exceptional circumstances were included 
in this report.  
 
 
4.1 EMA’s considerations  
and additional requirements 
Two of the main questions we wanted to answer were; what were the main 
considerations of the CHMP to licence the included drugs under exceptional 
circumstances and what were the additional requirements for the marketing 
authorisation holder?  
Two of the drugs, nelarabine and clofarabine, received a marketing authori-
sation under exceptional circumstances, clearly because of the very small size 
of the population. ALL and LBL are diseases which have gained better and 
better outcomes in the past decades and fortunately there are not that much 
patients in second relapse. Secondly, even in the absence of adequately con-
trolled trials, nelarabine and clofarabine treatment achieved meaningful re-
sponse rates and duration of response in a significant proportion of patients, 
said the CHMP. The really short life-expectancy in patients in second re-
lapse and the possibility to reach long-term survival with both nelarabine and 
clofarabine followed by HSCT shows the actual benefit to patients. Of course 
there are many uncertainties regarding the safety profiles, but those should 
be tackled by the specific obligations required by the CHMP. 
For clofarabine the initial requests by the CHMP concerned only the user’s 
information package and a voluntary adverse event reporting system. During 
the 3rd annually reassessment, additional obligations were added concerning 
population pharmacokinetics and dose adjustments in patients with moder-
ate renal impairments. In the monitoring of adverse effects, extra attention 
was to be given to the monitoring of veno-occlusive disease after HSCT. For 
nelarabine the CHMP required data from an on-going phase III Children’s 
Oncology Group study and a post-marketing surveillance study, to better de-
fine the safety profile. For both drugs there were no requirements concern-
ing additional efficacy data, which reflects the opinion of the CHMP that 
they achieved meaningful responses.  
A review of the literature revealed barely any new information on single-
agent treatment for the licenced indications, but fortunately clofarabine and 
nelarabine are currently tested in multiple multi-agent regimens in several 
clinical trials. 
Histamine dihydrochloride was authorised only after a re-examination and 
by majority decision, not by consensus. It was the only drug with a random-
ised phase III trial, owing to the much larger target population; patients 
with AML in remission. Rarity of the disease is therefore not clearly stated 
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as the ground for exceptional circumstances. In fact, the grounds for excep-
tional circumstances are not clear at all. Statistically significant results were 
only demonstrated for the surrogate endpoint leukaemia-free-survival, but 
not for overall survival.  
For histamine dihydrochloride two additional studies were requested. A 
clinical study to evaluate the biomarkers and pharmacologic endpoints of 
histamine dihydrochloride plus low dose interleukin-2 in approximately 100 
adults, to be completed in the second quarter of 2013 and a clinical study to 
evaluate minimal residual disease for the assessment of the anti-leukaemic 
activity of histamine dihydrochloride plus low dose interleukin-2 in approxi-
mately 150 adult patients, to be completed in the second quarter of 2013. 
This is in line with the uncertainties and disagreement regarding the effi-
cacy. In favour of histamine dihydrochloride are the relatively mild side-
effects. Information from clinicaltrials.gov and the EMA website is unfortu-
nately suggesting that the progress in the compliance to the CHMP require-
ments is rather slow.  
Trabectedin, like clofarabine and nelarabine, received its marketing authori-
sation under exceptional circumstances due to the rarity of the disease. The 
literature search however, implies that soft tissue sarcoma is not nearly as 
rare as ALL or LBL in second relapse. Subtypes of STS are indeed rare, and 
are considered too rare for adequately powered randomised controlled trials 
by the CHMP. What is contradictory to this statement is that trabectedin is 
licenced for all types of STS, although it was mainly tested in leiomyo- and 
liposarcoma. It is also not clear why it was not possible to perform a com-
parison to best supportive care. With respect to the safety of trabectedin, 
much more information was already available, since a lot of patients had 
been treated in compassionate use programs.  
For trabectedin the CHMP required the MAH to elucidate whether predic-
torsof response to trabectedin in patients with soft tissue sarcoma could bei-
dentified. The final study report was to be submitted by 30 June 2012, but is 
still awaited by the EMA. Outside of the trials of the manufacturer, trabect-
edin has been tested in numerous clinical trials in the past few years and 
even extended its licence to a second indication. It is likely that more infor-
mation will become available on the efficacy in different subtypes of STS. 
Table 4.1-1: Compliance to additional requirements requested by the CHMP 
 Clofarabine Nelarabine Trabectedin Histamine dihydrochloride 
Year of 
authorisation 2006 2007 2007 2008 
Requirements for 
additional data 
Safety and 
pharmacokinetic data 
Safety data Predictors of 
response 
Biomarkers, pharmacologic 
endpoints and minimal 
residual disease 
Delivered Yes Partly No No 
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4.2 Reimbursement evaluations 
When analysing the reimbursement decisions, it becomes clear that CVZ 
and NICE put a lot more effort into their assessments than RIZIV, HAS and 
SMC. In the assessments of RIZIV, when it comes to effectiveness and 
safety, no opinion is given on the quality of the evidence at all; they consist 
merely of a short summary of outcomes and adverse effects. The assessments 
of HAS are a little more extensive, but not very critical either. Both agen-
cies have not rejected any of the assessed drugs.  
SMC does not perform really extensive evaluations, but is more critical of 
the submitted evidence on effectiveness, safety and cost-effectiveness. As they 
apply a strict cost-effectiveness threshold, not all the drugs were recom-
mended. Clofarabine and nelarabine were recommended for restricted use, 
but histamine dihydrochloride and trabectedin were both not recommended.  
The single technology evaluations of NICE are an extensive, but also time 
consuming process. The evaluation of trabectedin is very thorough and there-
fore provides an opportunity for trabectedin to be widely implemented into 
practice in England. The other three drugs have not been evaluated, but the 
publication by O’Connor et al, 2011 [44] shows that clofarabine is being 
used in England.  
CVZ has evaluated three of the four drugs and recommended two of them. 
Their assessments are thorough and critical and separate the therapeutic 
and economic aspect. Drugs are not always recommended. As coverage with 
evidence development is always a condition for orphan or really expensive 
inpatient drugs, all drugs will be re-evaluated after about four years.  
Table 4.2-1: Reimbursement decisions per agency 
Reimbursement Clofarabine Nelarabine Trabectedin 
Histamine 
dihydrochloride 
SMS Restricted Restricted No No 
HAS Yes Yes Yes Yes 
CVZ Yes NA Yes No 
RIZIV Restricted Yes Yes NA 
NICE NA NA Yes, with PAS NA 
Abbreviations: CVZ – College voor Zorgverzekeringen, HAS – Haute Autorité de Santé, NICE – National Institute for Health 
and Clinical Excellence, RIZIV – Rijks Instituut voor Ziekte – en Invaliditeits Verzekering, SMC – Scottish Medicines 
Consortium, NA – Not applicable, PAS – Patient access scheme 
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4.3 Patient access and patient access schemes 
There was only one patient access scheme identified. NICE recommended 
trabectedin after the manufacturer proposed a patient access scheme in which 
it is agreed that the acquisition costs of trabectedin for treatment needed af-
ter the fifth cycle are met by the manufacturer.  
Coverage with evidence development is always required in the Netherlands 
for inpatient pharmaceuticals applying for additional financing. Usually this 
is paid for by the manufacturer, but in the case of trabectedin, the research 
is financed by The Netherlands Organisation for Health Research and De-
velopment. Since the request for additional financing of these drugs is done 
by the clinicians or hospital organisations and not by the manufacturer, it is 
not necessarily a patient access scheme.  
In the end the most important question is if patients actually gained access 
to drugs through the market authorisation under exceptional circumstances. 
This can unfortunately not completely be extracted from just the reimburse-
ment decisions. For the Netherlands and England a negative opinion does 
not strictly mean that a drug is not accessible, because hospitals can decide 
to pay for it. It is however unlikely. In the case that a drug is not assessed, 
access to it is rather unpredictable. In France, Belgium and Scotland how-
ever, a drug certainly needs a positive recommendation to be accessible.  
In France all four drugs received a positive recommendation and nelarabine, 
clofarabine and trabectedin are on the T2A list for additional funding. This 
makes it very probable that French patients have access to all four drugs.  
In Belgium the three drugs that were assessed, nelarabine, clofarabine and 
trabectedin, received a positive recommendation and are reimbursed. They 
are likely to be accessible for all patients. Histamine hydrochloride was not 
evaluated and is therefore not reimbursed. Although it is not as expensive as 
the other three drugs, it is unlikely that it’s affordable to many of the patients. 
NICE recommended trabectedin, which makes it mandatory to be available. 
Since England works with a negative list, the other three drugs are in theory 
reimbursable. Clofarabine has been used in practice, but it is not clear to 
which extent.  
For Scotland it is more clear which drugs are available. Only nelarabine and 
clofarabine got a positive recommendation under specific conditions. Tra-
bectedin and histamine dihydrochloride are very likely not accessible. Within 
the NHS system however, Scottish patients can travel to England to receive 
treatment. With the very strict cost-effectiveness criteria applied by the SMC, 
a lot of new medicines will likely not or with a delay be available in Scot-
land.  
In the Netherlands a positive recommendation is not a necessity for treat-
ment in the hospitals. Histamine dihydrochloride is an outpatient pharma-
ceutical and with the negative recommendation therefore not reimbursed. 
The conditional funding for trabectedin and clofarabine made the drugs ac-
cessible in certain academic hospitals. With the Netherlands being so small, 
they should be accessible to all patients. Nelarabine was not evaluated be-
cause it wouldn’t reach the cost threshold for additional funding. Hospitals 
have the option to pay it from their budget.  
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4.4 Conclusions and recommendations 
With the authorisation of oncology drugs under exceptional circumstances 
the EMA has partially succeeded in providing safe and effective drugs to pa-
tients with very rare cancers. For nelarabine and clofarabine the additional 
clinical data up to now were limited, but several clinical trials are planned 
and the benefit to patients has been shown. When evaluated by reimburse-
ment agencies, these two drugs always received a positive recommendation, 
which makes them accessible to patients.  
For trabectedin a lot of new information has become available and the indi-
cation was even extended. The reason for the SMC to not recommend it, was 
the cost-effectiveness. For trabectedin it can be argued that the authorisation 
under exceptional circumstances wasn’t completely justified, since STS is not 
as rare. The STS subtypes however, are. 
In the case of HDC the story is not that successful. The methodological weak-
nesses in the pivotal trial made CVZ and SMC issue a negative recommen-
dation and the by the CHMP requested trials have still not been performed. 
Time will tell if histamine dihydrochloride can become a successful treat-
ment.  
The criteria for authorisation under exceptional circumstances are not strictly 
defined, which gives the CHMP more freedom to apply this policy when 
they think it will be of benefit to the patient. This is acceptable, but a clearer 
statement of the justification is welcome. Additional requirements by the 
CHMP are often not met within the set time-frame.  
It is clear that EMA and reimbursement agencies have a different perspec-
tive when they evaluate a drug. As innovative orphan drugs are introduced 
on the market, it cannot always be expected that they immediately prove 
their cost-effectiveness, they might be of great benefit to the patients how-
ever.  
To retain the development of medicines for very rare diseases, it is important 
that industry, EMA and reimbursement agencies consult with each other. 
Scientific advice to the industry by EMA is highly recommended. Addition-
ally the industry should pay more attention to the requirements of the ‘fourth 
hurdle’; for example include the collection of utility data in the trial design, 
which is necessary for cost-effectiveness assessments. In return a new anti-
cancer drug could be given some time to prove itself in clinical practice. 
Conditional coverage with evidence development, as performed in the Neth-
erlands, seems a good option. The involvement of the clinicians is an advan-
tage, since small pharmaceutical companies may not always have the exper-
tise and financial means to perform this evidence development by them-
selves in a reasonable time-frame. It is then in the interest of the patient that 
the additional funding for this research is available. Since the patient popu-
lations in these cases are small, international collaborations are highly rec-
ommended. EU funding would then be a possibility.  
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justification for 
authorisation under 
exceptional 
circumstances 
more collaboration 
between the industry, 
EMA and reimbursement 
agencies is needed in the 
development of drugs 
for very rare diseases 
 
conditional coverage 
with evidence 
development is a good 
option  
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